Advertisement
"The addition of Dr. Krasner to our team provides Biodel with stronginternal clinical and regulatory leadership and we expect him to play animportant role in the clinical development of our product candidates," saidDr. Solomon Steiner, Chief Executive Officer and Chairman of Biodel. "Dr.Krasner's depth of knowledge in endocrinology and insulin, coupled with hisexperience developing late stage drug candidates will be valuable in advancingour suite of VIAject(TM) products to market."
Advertisement
Dr. Andreas Pfuetzner, Biodel's current Chief Medical Officer will remainon Biodel's management team as the Company's Chief Medical Officer in Europeand as a member of the Company's Scientific Advisory Board.
"I look forward to working closely with my esteemed colleague to advanceVIAject(TM) through the NDA phase of development," said Professor Dr. AndreasPfuetzner.
Dr. Krasner joins the Company from Pfizer Global Research and Developmentwhere he was Director of the Department of Clinical Research MetabolicDiseases and responsible for the design, execution, clinical analysis, andreporting of multiple, global clinical trials supporting registration of latestage drug candidates. Dr. Krasner currently serves as a consulting physicianat the Joslin Diabetes and Endocrinology Center of the Lawrence and MemorialHospital in New London, Connecticut. Dr. Krasner holds a B.S. from theMedical Education Honors Program at Northwestern University and a M.D. fromNorthwestern University Medical School. He completed his residency at JohnsHopkins Hospital in internal medicine and subsequently received a fellowshipfrom Johns Hopkins Hospital in endocrinology and metabolism.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on thedevelopment and commercialization of innovative treatments for endocrinedisorders, such as diabetes and osteoporosis. Biodel's product candidates aredeveloped by using VIAdel(TM) technology, which reformulates existingFDA-approved peptide drugs. The Company's lead product candidate,VIAject(TM), is an ultra rapid-acting injectable meal-time insulin indevelopment for use by patients with Type 1 or Type 2 diabetes. VIAject(TM)is currently being tested in two pivotal Phase III clinical trials. Biodel'spipeline also includes VIAtab(TM), a sublingual tablet formulation of insulinin the Phase I stage of clinical testing, and two pre-clinical osteoporosisproduct candidates. For further information regarding Biodel, please visitthe Company's website at www.biodel.com.
BIOD-G
SOURCE Biodel Inc.
